Strokes occur when blood flow to the brain is interrupted by vessel blockage or rupture, leading to acute brain injury. They are a major source of mortality and long-term disability.
A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
The Mississippi Department of Environmental Quality issued an air permit to xAI for 41 gas turbines to power its Colossus II data center, despite a lawsuit threat from the NAACP alleging Clean Air Act violations and community concerns about air quality impacts.
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
U.S. regulators have received more than 1,400 reports since 2021 involving AI-enabled surgical devices, including allegations of botched surgeries and misidentified body parts. The FDA has authorized over 1,300 AI-integrated medical devices.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02850081 |
Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes |
TERMINATED | PHASE3 |
